About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTHâ„¢ or to request a representative, visit YCANTHPro.com
Key Publications
Publication & Posters
Molluscum Contagiosum Publications
Molluscum Contagiosum Background
Molluscum Epidemiology and Quality of Life Impact
Molluscum Pathology
Association Between Molluscum Contagiosum and Atopic Dermatitis
Current Management for Molluscum Contagiosum
Current Treatment Practices for Molluscum Contagiosum
Cantharidin Mechanism of Action
Compounded Cantharidin for the Treatment of Molluscum Contagiosum
Use of VP-102 for Molluscum Contagiosum*
Common Warts Publications
Common Warts Background Information
Current Management of Common Warts
Treatment Landscape of Common Warts
Cantharidin Use in Common Warts
Use of VP-102 in Common Warts*
External Genital Warts Publications
External Genital Warts Background
External Genital Warts Epidemiology and Quality of Life Impact
External Genital Warts Pathology and Risk of Malignancy
Current Management of Genital Warts
Use of VP-102 for External Genital Warts*
Plantar Warts Publications
Plantar Warts Background Information
Current Management of Plantar Warts
Treatment Landscape of Plantar Warts
Cantharidin Use in Plantar Warts
Non-Melanoma Skin Cancer Publications
Skin Cancer Background
General Information on Skin Cancer
Squamous Cell Carcinoma
Basal Cell Carcinoma
Current Management of Non-Melanoma Skin Cancer
Non-Melanoma Skin Cancer
Squamous Cell Carcinoma
Basal Cell Carcinoma
About LTX-315
LTX-315 Mechanism of Action
LTX-315 Basic/Background Research
LTX-315 Clinical Data
About VP-315**
VP-315, a Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma
*VP-102 and LTX-315 have not been approved by the FDA